https://aktiv8.io/news/n1s5lwmx/cisive-extends-oracle-partnership-as-the-only-oracle-independent-software-vendor-isv-partn 2026-09-15 never 0.6 https://aktiv8.io/news/n1hmwarv/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-for-bezuclastinib- 2026-09-15 never 0.6 https://aktiv8.io/news/nknscbj/applied-photonix-launches-virozap-the-first-fda-cleared-medical-device-for-in-duct-air-dis 2026-09-15 never 0.6 https://aktiv8.io/news/nunxwo/lundbeck-prepares-for-second-phase-3-trial-of-epilepsy-drug-candidate-medwatch-com 2026-09-15 never 0.6 https://aktiv8.io/news/n1i5riwv/stat-vera-kidney-drug-trutakna-shows-strong-final-results-in-phase-3-trial 2026-09-15 never 0.6 https://aktiv8.io/news/n1c87mq1/keeps-biopharma-s-idetrexed-wins-korean-phase-2-ind-approval-korea-biomedical-review 2026-09-15 never 0.6 https://aktiv8.io/news/n1bemnk8/fda-accepts-curi-bio-s-letter-of-intent-into-istand-program-to-qualify-3d-neuromuscular-ju 2026-09-15 never 0.6 https://aktiv8.io/news/n1ezb5da/rocket-pharmaceuticals-announces-fda-alignment-on-path-to-complete-pivotal-phase-2-trial-o 2026-09-15 never 0.6 https://aktiv8.io/news/nwyn1ty/stat-fda-takes-applications-for-new-program-to-shorten-drug-approval-times 2026-09-15 never 0.6 https://aktiv8.io/news/nafgulo/powerful-medical-receives-fda-de-novo-approval-for-pmcardio-queen-of-hearts-its-ai-ecg-mod 2026-09-15 never 0.6 https://aktiv8.io/news/n1q0e3rp/blossomhill-therapeutics-presents-updated-data-from-ongoing-phase-1-2-solara-trial-demonst 2026-09-15 never 0.6 https://aktiv8.io/news/nivya3k/definium-tees-up-regulatory-submission-for-psychedelic-on-phase-iii-hat-trick 2026-09-15 never 0.6 https://aktiv8.io/news/nsiavzh/one04-therapeutics-launches-on-encouraging-cpv-104-phase-1-interim-results-and-plans-to-ex 2026-09-15 never 0.6 https://aktiv8.io/news/n1jsmgx6/south-korean-authorities-raid-kosdaq-biotech-firm-over-insider-trading-ahead-of-global-pha 2026-09-15 never 0.6 https://aktiv8.io/news/n7dtzif/ori-biotech-announces-10-year-120m-partnership-to-advance-automated-manufacturing-for-comm 2026-09-15 never 0.6 https://aktiv8.io/news/n1r5eysf/connect-biopharma-announces-positive-preliminary-topline-data-from-its-global-phase-2-stud 2026-09-15 never 0.6 https://aktiv8.io/news/nqunaxq/polaritybio-announces-fda-acceptance-for-filing-of-skinte-bla-with-priority-review-in-diab 2026-09-15 never 0.6 https://aktiv8.io/news/n1f2z6d8/skyhawk-therapeutics-announces-final-fifteen-month-results-from-phase-1-2-clinical-trial-o 2026-09-15 never 0.6 https://aktiv8.io/news/n1hwbwua/kestrel-therapeutics-receives-fda-fast-track-designation-for-kst-6051-a-potential-best-in- 2026-09-15 never 0.6 https://aktiv8.io/news/nx0ravd/openevidence-and-penn-medicine-partner-to-advance-medical-intelligence-for-global-health-b 2026-09-15 never 0.6 https://aktiv8.io/news/n1gs41dh/definium-s-dt120-odt-meets-primary-endpoint-in-phase-3-gad-study-the-clinical-trial-vangua 2026-09-15 never 0.6 https://aktiv8.io/news/n1d7l1s1/connect-biopharma-announces-positive-preliminary-topline-data-from-its-global-phase-2-stud 2026-09-15 never 0.6 https://aktiv8.io/news/nq3hb3u/biovie-announces-topline-results-from-phase-2-address-lc-trial-evaluating-bezisterim-for-t 2026-09-15 never 0.6 https://aktiv8.io/news/n1f0cura/arrowhead-pharmaceuticals-announces-interim-topline-clinical-data-for-the-first-dual-funct 2026-09-15 never 0.6 https://aktiv8.io/news/nd80sa2/rocket-pharmaceuticals-announces-fda-alignment-on-path-to-complete-pivotal-phase-2-trial-o 2026-09-15 never 0.6 https://aktiv8.io/news/nsyxz63/arrowhead-pharmaceuticals-announces-interim-topline-clinical-data-for-the-first-dual-funct 2026-09-15 never 0.6 https://aktiv8.io/news/np00x8b/coya-therapeutics-announces-enrollment-of-100th-participant-in-phase-2-3-alstars-trial-of- 2026-09-15 never 0.6 https://aktiv8.io/news/n1u3xgvn/microstructure-imaging-receives-fda-clearance-for-micsi-pet-bringing-mr-guided-enhancement 2026-09-15 never 0.6 https://aktiv8.io/news/ndm5p2a/gilead-and-paho-announce-milestone-partnership-to-accelerate-access-to-twice-yearly-lenaca 2026-09-15 never 0.6 https://aktiv8.io/news/n1r70eg9/ledger-run-and-ice-global-consulting-expand-strategic-partnership-to-advance-clinical-tria 2026-09-15 never 0.6 https://aktiv8.io/news/ndpd10a/biovie-announces-topline-results-from-phase-2-address-lc-trial-evaluating-bezisterim-for-t 2026-09-15 never 0.6 https://aktiv8.io/news/nly3clu/definium-therapeutics-jumps-20-after-third-phase-3-win-for-lsd-based-anxiety-drug-finance- 2026-09-14 never 0.6 https://aktiv8.io/news/n1mig42x/agomab-announces-positive-phase-1-results-for-agmb-447-in-patients-with-idiopathic-pulmona 2026-09-14 never 0.6 https://aktiv8.io/news/n16pa1ex/akebia-therapeutics-announces-first-patient-dosed-in-phase-2-basket-trial-of-ebribafusp-in 2026-09-14 never 0.6 https://aktiv8.io/news/n1vgyfou/ascletis-pharma-sehk-1672-following-fda-clearance-looks-about-right-at-3-8x-p-b-simplywall 2026-09-14 never 0.6 https://aktiv8.io/news/n1usgnn/trans-canada-gold-announces-1-5-million-cdn-non-brokered-private-placement-for-phase-2-dri 2026-09-14 never 0.6 https://aktiv8.io/news/n15i0746/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-c 2026-09-14 never 0.6 https://aktiv8.io/news/n1gukqis/bio-usawa-and-axmed-partner-to-expand-access-to-affordable-biologic-medicines-across-afric 2026-09-14 never 0.6 https://aktiv8.io/news/n1vlh83q/enhertu-demonstrated-a-median-progression-free-survival-of-14-3-months-as-first-line-thera 2026-09-14 never 0.6 https://aktiv8.io/news/n2x3imf/u-s-fda-accepts-new-drug-application-under-priority-review-for-takeda-s-zasocitinib-in-mod 2026-09-14 never 0.6 https://aktiv8.io/news/n14ja2h7/dare-bioscience-announces-peer-reviewed-publication-of-phase-1-sildenafil-cream-study-in-m 2026-09-14 never 0.6 https://aktiv8.io/news/n10fxi91/roche-medilink-notch-phase-3-lung-cancer-win-but-trail-gsk-on-cross-trial-survival 2026-09-14 never 0.6 https://aktiv8.io/news/n1j6y79z/biovie-to-host-conference-call-to-discuss-topline-data-from-phase-2-address-lc-trial-and-t 2026-09-14 never 0.6 https://aktiv8.io/news/n2pen4n/vyriad-begins-phase-1-clinical-trial-for-lead-in-vivo-car-t-cell-therapy-vv169-following-f 2026-09-14 never 0.6 https://aktiv8.io/news/nxk0iho/sapience-therapeutics-announces-fda-acceptance-of-investigational-new-drug-application-for 2026-09-14 never 0.6 https://aktiv8.io/news/n13ptnyq/u-s-fda-accepts-new-drug-application-under-priority-review-for-takeda-s-zasocitinib-in-mod 2026-09-14 never 0.6 https://aktiv8.io/news/ntlyk9x/organon-announces-us-fda-has-accepted-for-review-a-supplemental-new-drug-application-for-m 2026-09-14 never 0.6 https://aktiv8.io/news/n4qrmm2/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalert 2026-09-14 never 0.6 https://aktiv8.io/news/nr1hz8w/sapience-therapeutics-announces-fda-acceptance-of-investigational-new-drug-application-for 2026-09-14 never 0.6 https://aktiv8.io/news/n5bu2uo/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt 2026-09-14 never 0.6 https://aktiv8.io/news/n1nohcmz/cosi-introduces-market-partner-program-offering-a-new-licensing-model-for-local-foodservic 2026-09-14 never 0.6 https://aktiv8.io/news/nz2hku9/pharmazz-inc-receives-u-s-fda-orphan-drug-designation-for-sovateltide-for-the-treatment-of 2026-09-14 never 0.6 https://aktiv8.io/news/nwoxenj/tuhura-biosciences-receives-fda-study-may-proceed-notice-and-ind-clearance-for-the-evaluat 2026-09-14 never 0.6 https://aktiv8.io/news/nejmapw/astrazeneca-s-newly-approved-pill-fails-frontline-breast-cancer-study 2026-09-14 never 0.6 https://aktiv8.io/news/n15immf4/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt 2026-09-14 never 0.6 https://aktiv8.io/news/n3pg4dj/cullinan-taiho-showcase-6-month-survival-benefit-in-phase-3-trial-for-advanced-lung-cancer 2026-09-14 never 0.6 https://aktiv8.io/news/n1h3ktk8/altruist-biologics-congratulates-partner-longbio-pharma-on-the-bla-acceptance-of-lp-003-by 2026-09-14 never 0.6 https://aktiv8.io/news/np4ra4z/phio-announces-key-development-milestone-for-ph-762-with-fda-submission-supporting-next-st 2026-09-14 never 0.6 https://aktiv8.io/news/n3jzcbi/santa-ana-bio-announces-first-subjects-dosed-in-phase-1-study-of-sab01-to-treat-autoimmune 2026-09-14 never 0.6 https://aktiv8.io/news/nqpjxq5/oxeia-to-host-investor-webinar-with-nfl-s-alex-smith-on-what-could-become-the-first-fda-ap 2026-09-14 never 0.6 https://aktiv8.io/news/n4l1n5m/tuhura-biosciences-receives-fda-study-may-proceed-notice-and-ind-clearance-for-the-evaluat 2026-09-14 never 0.6 https://aktiv8.io/news/n65lik5/janux-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-janx013-janx-stock-ne 2026-09-14 never 0.6 https://aktiv8.io/news/n12udyet/immunocore-announces-target-enrollment-achieved-in-phase-3-tebe-am-trial-of-kimmtrak-in-pr 2026-09-14 never 0.6 https://aktiv8.io/news/n1xk4w08/biomunex-announces-the-upcoming-start-of-clinical-development-of-ipn60330-the-first-mait-e 2026-09-14 never 0.6 https://aktiv8.io/news/n13jzxbf/aptar-pharma-and-massachusetts-general-hospital-collaborate-on-platform-to-establish-predi 2026-09-14 never 0.6 https://aktiv8.io/news/n8hws5k/biontech-and-oncoc4-report-updated-phase-3-data-showing-gotistobart-nearly-doubles-overall 2026-09-14 never 0.6 https://aktiv8.io/news/nnuzaa/genfit-advances-nangibotide-in-phase-2-clinical-investigation-in-aclf 2026-09-14 never 0.6 https://aktiv8.io/news/n7b690v/altruist-biologics-congratulates-partner-longbio-pharma-on-the-bla-acceptance-of-lp-003-by 2026-09-14 never 0.6 https://aktiv8.io/news/n1iojvej/trastuzumab-botidotin-shows-11-1-month-pfs-vs-t-dm1-in-phase-3-trial-the-clinical-trial-va 2026-09-14 never 0.6 https://aktiv8.io/news/n13zv0nc/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-c 2026-09-14 never 0.6 https://aktiv8.io/news/n13oskow/scholar-rock-wins-fda-approval-for-isembyld-the-pharma-letter 2026-09-14 never 0.6 https://aktiv8.io/news/n3r9ifv/tuhura-biosciences-receives-fda-study-may-proceed-notice-and-ind-clearance-for-the-evaluat 2026-09-14 never 0.6 https://aktiv8.io/news/n44uvip/fda-compliance-guide-high-quality-mobility-lift-recliner-chair-supplier-selection-the-geek 2026-09-14 never 0.6 https://aktiv8.io/news/nds8whh/zipalertinib-plus-chemotherapy-demonstrates-6-month-median-progression-free-survival-benef 2026-09-14 never 0.6 https://aktiv8.io/news/nsl5iuk/fda-grants-bright-path-amt-designation-as-it-moves-to-reshore-america-s-medicines-and-redu 2026-09-14 never 0.6 https://aktiv8.io/news/n1fo5eip/basilea-announces-start-of-clinical-study-by-partner-asahi-kasei-therapeutics-in-japan-wit 2026-09-14 never 0.6 https://aktiv8.io/news/nmh60w3/nanobiotix-announces-complete-full-cohort-phase-1-results-for-jnj-1900-nbtxr3-in-inoperabl 2026-09-14 never 0.6 https://aktiv8.io/news/nc85m20/abelzeta-receives-fda-ind-clearance-for-phase-1b-2-clinical-trial-of-c-car168-in-progressi 2026-09-14 never 0.6 https://aktiv8.io/news/nlyhy2f/radiation-business-solutions-to-evaluate-new-partners-for-anoma-cancer-collective-at-astro 2026-09-14 never 0.6 https://aktiv8.io/news/n1mmnr58/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt 2026-09-14 never 0.6 https://aktiv8.io/news/nqjnj1u/etienna-bio-completes-fda-interact-meeting-for-etb-001 2026-09-14 never 0.6 https://aktiv8.io/news/n970fi8/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-for-postpartum-depressio 2026-09-14 never 0.6 https://aktiv8.io/news/n6afvfa/abelzeta-receives-fda-ind-clearance-for-phase-1b-2-clinical-trial-of-c-car168-in-progressi 2026-09-14 never 0.6 https://aktiv8.io/news/nfp2n2l/altruist-biologics-congratulates-partner-longbio-pharma-on-the-bla-acceptance-of-lp-003-by 2026-09-14 never 0.6 https://aktiv8.io/news/n1wf23h5/nanobiotix-announces-complete-full-cohort-phase-1-results-for-jnj-1900-nbtxr3-in-inoperabl 2026-09-14 never 0.6 https://aktiv8.io/news/n11p7hiz/an-anxiety-treatment-met-every-key-goal-in-a-late-stage-trial-an-fda-meeting-is-planned-fo 2026-09-14 never 0.6 https://aktiv8.io/news/ncai1bq/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-for-postpartum-depressio 2026-09-14 never 0.6 https://aktiv8.io/news/n4yyl01/nasus-pharma-announces-fda-clearance-to-initiate-clinical-study-of-ns002-in-the-treatment- 2026-09-14 never 0.6 https://aktiv8.io/news/n1xpymk2/roche-medilink-notch-phase-3-lung-cancer-win-but-trail-gsk-on-cross-trial-survival 2026-09-14 never 0.6 https://aktiv8.io/news/n1wb8hwy/corbus-posts-phase-1-obesity-data-for-drug-mechanism-that-defeated-novo-sanofi 2026-09-14 never 0.6 https://aktiv8.io/news/nulwguv/altruist-biologics-congratulates-partner-longbio-pharma-on-the-bla-acceptance-of-lp-003-by 2026-09-14 never 0.6 https://aktiv8.io/news/n1jzplnq/definium-lsd-drug-goes-3-for-3-with-another-pivotal-anxiety-trial-win 2026-09-14 never 0.6 https://aktiv8.io/news/n1r23ze4/biontech-sets-survival-standard-in-hard-to-treat-cancer-ahead-of-pivotal-readout 2026-09-14 never 0.6 https://aktiv8.io/news/n1gg62ov/fda-clears-nasal-epinephrine-study-for-nasus-pharma-nsrx-targeting-anaphylaxis-stock-titan 2026-09-14 never 0.6 https://aktiv8.io/news/nyvm897/a-single-dose-of-pharmaceutical-lsd-cut-anxiety-scores-five-points-below-placebo-in-phase- 2026-09-14 never 0.6 https://aktiv8.io/news/n1ezc61e/definium-to-present-phase-3-anxiety-disorder-trial-results-monday-by-investing-com-investi 2026-09-14 never 0.6 https://aktiv8.io/news/n1qlxalc/pasithea-therapeutics-announces-presentation-of-initial-pas-004-clinical-data-from-ongoing 2026-09-14 never 0.6 https://aktiv8.io/news/ninmik/electra-aims-for-342m-ipo-to-power-inflammatory-drug-s-push-through-phase-3 2026-09-14 never 0.6 https://aktiv8.io/news/n1ud6icd/armata-pharmaceuticals-receives-u-s-fda-breakthrough-therapy-designation-for-ap-sa02 2026-09-14 never 0.6 https://aktiv8.io/news/n12vb5ha/data-safety-monitoring-board-dsmb-recommends-continuing-briacell-s-phase-3-metastatic-brea 2026-09-14 never 0.6 https://aktiv8.io/news/n15rstok/definium-therapeutics-dftx-posts-third-positive-phase-3-anxiety-result-ahead-of-planned-nd 2026-09-14 never 0.6 https://aktiv8.io/news/n1mkbpf7/u-s-fda-accepts-new-drug-application-under-priority-review-for-takeda-s-zasocitinib-in-mod 2026-09-14 never 0.6 https://aktiv8.io/news/n5rbz6a/cullinan-therapeutics-to-host-virtual-investor-event-on-phase-3-rezilient3-zipalertinib-da 2026-09-14 never 0.6 https://aktiv8.io/news/nxtb5jh/contineum-therapeutics-reports-phase-2-results-for-jnj-5120-pipe-307-for-the-treatment-of- 2026-09-14 never 0.6 https://aktiv8.io/news/n63aluc/organon-announces-us-fda-has-accepted-for-review-a-supplemental-new-drug-application-for-m 2026-09-14 never 0.6 https://aktiv8.io/news/n1cyyjt0/gsk-and-roche-chinese-adc-bets-deliver-positive-phase-3-data-in-sclc-european-biotechnolog 2026-09-14 never 0.6 https://aktiv8.io/news/ngvjgno/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-today-to-feature-zipalert 2026-09-14 never 0.6 https://aktiv8.io/news/ngs3d7i/fda-grants-bright-path-amt-designation-as-it-moves-to-reshore-america-s-medicines-and-redu 2026-09-14 never 0.6 https://aktiv8.io/news/n1jdluv1/angelis-oncology-launches-acquires-plx038-and-initiates-clinical-trial-in-glioblastoma 2026-09-14 never 0.6 https://aktiv8.io/news/nvmvwzf/biovie-to-host-conference-call-to-discuss-topline-data-from-phase-2-address-lc-trial-and-t 2026-09-14 never 0.6 https://aktiv8.io/news/n8kkha1/biontech-nasdaq-bntx-lung-cancer-drug-extends-survival-vs-chemo-in-phase-3-stock-titan 2026-09-14 never 0.6 https://aktiv8.io/news/n14w22mk/leios-therapeutics-announces-positive-end-of-phase-2-meeting-with-fda-for-10xb-101-for-mod 2026-09-14 never 0.6 https://aktiv8.io/news/nmq8w3o/positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-d 2026-09-14 never 0.6 https://aktiv8.io/news/n7ztucz/jamjoom-pharma-signs-exclusive-mea-licensing-deal-for-nordic-pharma-s-lacrifill-dry-eye-ge 2026-09-13 never 0.6 https://aktiv8.io/news/nkak3zy/jamjoom-pharma-signs-exclusive-licensing-and-commercialization-agreement-with-nordic-pharm 2026-09-13 never 0.6 https://aktiv8.io/news/n11hcxvs/iza-bren-2-5-mg-kg-dose-advances-to-phase-3-in-egfr-mutated-nsclc-the-clinical-trial-vangu 2026-09-13 never 0.6 https://aktiv8.io/news/ndd1k4j/tam-peli-meets-primary-endpoint-for-relapsed-small-cell-lung-cancer-in-phase-iii-trial-the 2026-09-13 never 0.6 https://aktiv8.io/news/nir7tze/definium-therapeutics-to-discuss-topline-results-from-phase-3-panorama-study-in-generalize 2026-09-13 never 0.6 https://aktiv8.io/news/n19bp26g/roche-s-collaborator-medilink-announces-phase-iii-data-for-tam-peli-showing-significantly- 2026-09-13 never 0.6 https://aktiv8.io/news/n10teaz8/definium-to-present-phase-3-anxiety-disorder-trial-results-monday-investing-com 2026-09-13 never 0.6 https://aktiv8.io/news/nuk2i5d/zipalertinib-plus-chemotherapy-demonstrates-6-month-median-progression-free-survival-benef 2026-09-13 never 0.6 https://aktiv8.io/news/n1kf1r4a/sudarshan-pharma-acquires-9-50-stake-in-us-firm-medtherapy-biotech-scanx-trade 2026-09-13 never 0.6 https://aktiv8.io/news/n192y076/fda-approves-telix-s-brain-cancer-imaging-drug-pixclara 2026-09-13 never 0.6 https://aktiv8.io/news/n8vchkt/gc-biopharma-gets-phase-2-approval-for-covid-19-vaccine-thelec-net 2026-09-12 never 0.6 https://aktiv8.io/news/nz7wsu3/meant-health-expands-telehealth-access-to-fda-approved-glp-1-prescriptions-including-ozemp 2026-09-12 never 0.6 https://aktiv8.io/news/nzokp07/stat-breast-cancer-pill-from-astrazeneca-misses-mark-in-pivotal-trial 2026-09-12 never 0.6 https://aktiv8.io/news/n1ddtynu/galimedix-therapeutics-to-present-functional-feasibility-data-from-phase-2-edream-study-in 2026-09-11 never 0.6 https://aktiv8.io/news/nxpdeyd/this-week-in-charts-ra-s-insatiable-appetite-novartis-big-slide-and-a-reverse-merger-spree 2026-09-11 never 0.6 https://aktiv8.io/news/n1v4dq4k/fda-delays-approval-decision-for-exelixis-tyrosine-kinase-inhibitor-in-colorectal-cancer 2026-09-11 never 0.6 https://aktiv8.io/news/n1uxw13w/gc-biopharma-wins-approval-for-phase-2-covid-19-mrna-vaccine-trial-korea-biomedical-review 2026-09-11 never 0.6 https://aktiv8.io/news/npxe3ea/nrx-pharmaceuticals-nasdaq-nrxp-subsidiary-hope-therapeutics-begins-training-and-deploymen 2026-09-11 never 0.6 https://aktiv8.io/news/n5zj53u/this-week-in-charts-ra-s-insatiable-appetite-novartis-big-slide-and-a-reverse-merger-spree 2026-09-11 never 0.6 https://aktiv8.io/news/n1v4ymbg/lilly-completes-acquisition-of-ataibeckley-to-advance-therapies-for-treatment-resistant-de 2026-09-11 never 0.6 https://aktiv8.io/news/n1cv9q0i/cybin-cn-help-falls-5-91-as-clinical-stage-risk-and-phase-3-expectations-pressure-sentimen 2026-09-11 never 0.6 https://aktiv8.io/news/n1aq0tcw/stat-scholar-rock-wins-fda-approval-for-first-drug-to-target-sma-muscle-loss 2026-09-11 never 0.6 https://aktiv8.io/news/nv5tq0j/the-u-s-fda-grants-orphan-drug-designation-for-lundbeck-s-investigational-anti-acth-monocl 2026-09-11 never 0.6 https://aktiv8.io/news/niveh0z/how-achondroplasia-nda-progress-will-impact-bridgebio-pharma-stock-simplywall-st 2026-09-11 never 0.6 https://aktiv8.io/news/nskmhrj/the-u-s-fda-grants-orphan-drug-designation-for-lundbeck-s-investigational-anti-acth-monocl 2026-09-11 never 0.6 https://aktiv8.io/news/n14ykity/fda-delays-approval-decision-for-exelixis-tyrosine-kinase-inhibitor-in-colorectal-cancer 2026-09-11 never 0.6 https://aktiv8.io/news/n1c42imk/abbvie-drug-meets-phase-3-goal-in-menstrual-migraine-emj 2026-09-11 never 0.6 https://aktiv8.io/news/n7wfcng/lilly-completes-acquisition-of-ataibeckley-to-advance-therapies-for-treatment-resistant-de 2026-09-11 never 0.6 https://aktiv8.io/news/n1w3om8g/fda-halts-sk-biopharm-s-opcalim-novartis-12-billion-drug-fails-phase-3-finance-biggo-com 2026-09-11 never 0.6 https://aktiv8.io/news/n1xnk52u/biontech-sets-survival-standard-in-hard-to-treat-cancer-ahead-of-pivotal-readout 2026-09-11 never 0.6 https://aktiv8.io/news/n121kxo0/definium-lsd-drug-goes-3-for-3-with-another-pivotal-anxiety-trial-win 2026-09-11 never 0.6 https://aktiv8.io/news/n10hy8ck/scholar-rock-announces-fda-approval-of-isembyld-apitegromab-mstn-the-first-and-only-muscle 2026-09-11 never 0.6 https://aktiv8.io/news/n1ayme95/the-u-s-fda-grants-orphan-drug-designation-for-lundbeck-s-investigational-anti-acth-monocl 2026-09-11 never 0.6 https://aktiv8.io/news/nj73oux/nutromics-receives-fda-breakthrough-device-designation-businesswire-com 2026-09-11 never 0.6 https://aktiv8.io/news/nr88med/corbus-pharmaceuticals-to-host-conference-call-to-discuss-topline-data-from-canyon-1-clini 2026-09-11 never 0.6 https://aktiv8.io/news/n3selbz/gsk-s-hansoh-partnered-adc-lays-down-marker-for-lung-cancer-scrap-with-merck 2026-09-11 never 0.6 https://aktiv8.io/news/nv2yhvs/corbus-pharmaceuticals-to-host-conference-call-to-discuss-topline-data-from-canyon-1-clini 2026-09-11 never 0.6 https://aktiv8.io/news/nm1nuj5/astrazeneca-shares-phase-3-results-for-imfinzi-plus-imdelltra-in-extensive-stage-small-cel 2026-09-11 never 0.6 https://aktiv8.io/news/n1rfnsoy/takeda-pharmaceutical-tak-fda-approvals-pdufa-dates-drug-alerts-2026-tak-marketbeat 2026-09-11 never 0.6 https://aktiv8.io/news/n1jp6ltk/cullinan-taiho-showcase-6-month-survival-benefit-in-phase-3-trial-for-advanced-lung-cancer 2026-09-11 never 0.6 https://aktiv8.io/news/nmm5kff/biohaven-s-epilepsy-drug-hit-with-fda-clinical-hold 2026-09-11 never 0.6 https://aktiv8.io/news/n1n766m1/no-treatment-is-approved-for-menstrual-migraine-abbvie-s-drug-cut-migraine-days-in-a-trial 2026-09-10 never 0.6 https://aktiv8.io/news/n1f4t4w6/tae-life-sciences-achieves-iso-13485-certification-marking-a-major-milestone-in-quality-an 2026-09-10 never 0.6 https://aktiv8.io/news/nxrznf3/new-phase-2-clinical-trial-initiating-in-2027-evaluating-psilocybin-assisted-therapy-for-m 2026-09-10 never 0.6 https://aktiv8.io/news/n1ji75ez/definium-therapeutics-to-present-topline-data-from-phase-3-emerge-and-voyage-trials-across 2026-09-10 never 0.6 https://aktiv8.io/news/n4jkn0c/pharma-companies-turn-to-strategic-cdmo-partnerships-as-development-needs-evolve 2026-09-10 never 0.6 https://aktiv8.io/news/n1vdbn5q/stat-fda-expands-bayer-lung-cancer-drug-approval 2026-09-10 never 0.6 https://aktiv8.io/news/n13lzqzy/biovie-seeks-fda-meeting-to-plan-phase-3-trial-for-parkinson-s-drug-candidate-parkinson-s- 2026-09-10 never 0.6 https://aktiv8.io/news/n4q4f6f/medicus-pharma-publishes-abridged-final-phase-2-skinject-clinical-study-report-csr-results 2026-09-10 never 0.6 https://aktiv8.io/news/n194o9u3/u-s-fda-grants-priority-review-for-genentech-s-enspryng-for-mogad-an-autoimmune-disease-wi 2026-09-10 never 0.6 https://aktiv8.io/news/nvzl0cz/abl-diagnostics-texcell-strengthens-its-position-as-an-international-reference-in-safety-a 2026-09-10 never 0.6 https://aktiv8.io/news/njsiss/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-to-showcase-zipalertinib- 2026-09-10 never 0.6 https://aktiv8.io/news/n1o7im2a/abionyx-pharma-reaches-another-key-milestone-in-the-industrialization-of-cer-001-by-enteri 2026-09-10 never 0.6 https://aktiv8.io/news/n19cpara/revvity-signs-agreement-to-acquire-human-cell-design 2026-09-10 never 0.6 https://aktiv8.io/news/nhmlgzg/kallisio-expands-patient-access-to-stentra-an-fda-cleared-custom-mouthpiece-for-head-and-n 2026-09-10 never 0.6 https://aktiv8.io/news/n44qflf/medicus-pharma-publishes-abridged-final-phase-2-skinject-clinical-study-report-csr-results 2026-09-10 never 0.6 https://aktiv8.io/news/nq97irw/biolinerx-and-hemispherian-as-to-present-encouraging-glix1-preclinical-efficacy-data-and-i 2026-09-10 never 0.6 https://aktiv8.io/news/nqlmalk/palantir-and-fujitsu-deepen-partnership-to-advance-enterprise-ai-transformation-with-fujit 2026-09-10 never 0.6 https://aktiv8.io/news/np6cu14/quantum-biopharma-advances-multiple-sclerosis-drug-lucid-ms-toward-phase-2-trial-after-fda 2026-09-10 never 0.6 https://aktiv8.io/news/n11nk2xm/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-menstrual-mi 2026-09-10 never 0.6 https://aktiv8.io/news/n14x9l4v/seismic-pharmaceuticals-announces-the-enrollment-of-the-first-patient-in-the-global-phase- 2026-09-10 never 0.6 https://aktiv8.io/news/n1ed6swa/fda-clears-cu-anschutz-clinical-trial-using-engineered-immune-cells-to-fight-colorectal-ca 2026-09-10 never 0.6 https://aktiv8.io/news/n2t3xms/xcath-robotics-receives-fda-breakthrough-device-designation-for-the-iris-system-for-remote 2026-09-10 never 0.6 https://aktiv8.io/news/n1ip3bs4/biolinerx-and-hemispherian-as-to-present-encouraging-glix1-preclinical-efficacy-data-and-i 2026-09-10 never 0.6 https://aktiv8.io/news/n1yfnyd1/viamericas-announces-partnership-with-rcbc-as-direct-banking-partner-and-expands-payout-op 2026-09-10 never 0.6 https://aktiv8.io/news/n1nlal21/fda-expands-bayer-lung-cancer-drug-approval 2026-09-10 never 0.6 https://aktiv8.io/news/n1ki7sfg/trexo-robotics-receives-fda-clearance-launches-trexo-theo-first-pediatric-robotic-exoskele 2026-09-10 never 0.6 https://aktiv8.io/news/n1h2i13/gc-biopharma-enters-phase-2-for-homegrown-mrna-vaccine-targets-2028-rollout-seoul-economic 2026-09-10 never 0.6 https://aktiv8.io/news/nwic492/fda-places-partial-hold-on-biohaven-s-epilepsy-drug 2026-09-10 never 0.6 https://aktiv8.io/news/n17fiax2/harbour-biomed-advances-long-acting-antibody-candidate-to-phase-3-trial-vietnam-investment 2026-09-10 never 0.6 https://aktiv8.io/news/n3odacc/pharma-companies-turn-to-strategic-cdmo-partnerships-as-development-needs-evolve 2026-09-10 never 0.6 https://aktiv8.io/news/npw0ngl/kelun-biotech-partner-reports-positive-asthma-phase-2-trial-results-vietnam-investment-rev 2026-09-10 never 0.6 https://aktiv8.io/news/n1x14x0g/cullinan-therapeutics-to-present-phase-3-rezilient3-interim-data-on-zipalertinib-plus-chem 2026-09-10 never 0.6 https://aktiv8.io/news/ndwtaqw/stat-what-to-expect-from-uniqure-s-upcoming-huntington-s-gene-therapy-readout 2026-09-10 never 0.6 https://aktiv8.io/news/n1tlsf0q/immuno-oncology-pioneer-dr-michael-kalos-joins-kos-biotechnology-partners-as-venture-partn 2026-09-10 never 0.6 https://aktiv8.io/news/n1asx02h/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinic 2026-09-10 never 0.6 https://aktiv8.io/news/nlo28hz/beeline-medicines-phase-ii-sle-trial-of-afimetoran-meets-primary-endpoint 2026-09-10 never 0.6 https://aktiv8.io/news/nkxe9ze/fda-accepts-roche-s-enspryng-sbla-for-mogad-the-pharma-letter 2026-09-10 never 0.6 https://aktiv8.io/news/n1mhzggw/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-menstrual-mi 2026-09-10 never 0.6 https://aktiv8.io/news/n5zyx27/coppernico-signs-drill-contract-for-phase-2-drill-program-at-sombrero-cppmf-stock-news 2026-09-10 never 0.6 https://aktiv8.io/news/ngusfka/visionary-outlines-20-000-metre-phase-2-drill-program-to-grow-pt-leamington-resource-and-a 2026-09-10 never 0.6 https://aktiv8.io/news/n88yvq5/biolinerx-and-hemispherian-as-to-present-encouraging-glix1-preclinical-efficacy-data-and-i 2026-09-10 never 0.6 https://aktiv8.io/news/nxjybvf/lunit-announces-collaboration-with-10x-genomics-to-integrate-ai-enabled-pathology-analysis 2026-09-10 never 0.6 https://aktiv8.io/news/n198nvsj/definium-therapeutics-to-present-topline-data-from-phase-3-emerge-and-voyage-trials-across 2026-09-10 never 0.6 https://aktiv8.io/news/n1dqh8wg/comcast-and-fastly-partner-to-develop-next-generation-content-and-application-delivery-mod 2026-09-10 never 0.6 https://aktiv8.io/news/n1rm40n1/fda-clears-cu-anschutz-clinical-trial-using-engineered-immune-cells-to-fight-colorectal-ca 2026-09-10 never 0.6 https://aktiv8.io/news/n1cmox8w/all-randomized-pediatric-patients-to-continue-in-the-single-blind-extension-phase-of-jagua 2026-09-10 never 0.6 https://aktiv8.io/news/nnzyqjd/bionyra-pharma-announces-first-healthy-volunteers-dosed-in-phase-1-study-of-byn-001-a-long 2026-09-10 never 0.6 https://aktiv8.io/news/n17wnh2v/hagens-berman-alerts-capricor-therapeutics-inc-nasdaq-capr-investors-to-fda-review-extensi 2026-09-10 never 0.6 https://aktiv8.io/news/n3yx8lx/cabral-gold-announces-first-gold-pour-at-phase-1-mine-cuiu-cuiu-gold-district-brazil-cbgzf 2026-09-10 never 0.6 https://aktiv8.io/news/n1628rml/lake-victoria-gold-advances-imwelo-phase-3-land-programme-toward-final-approval-and-compen 2026-09-10 never 0.6 https://aktiv8.io/news/n1wd5tm8/lyell-immunopharma-completes-manufacturing-transfer-for-lyl273-and-provides-updated-timeli 2026-09-10 never 0.6 https://aktiv8.io/news/n1mtluqb/biolinerx-and-hemispherian-as-to-present-encouraging-glix1-preclinical-efficacy-data-and-i 2026-09-10 never 0.6 https://aktiv8.io/news/nc3sayo/immuno-oncology-pioneer-dr-michael-kalos-joins-kos-biotechnology-partners-as-venture-partn 2026-09-10 never 0.6 https://aktiv8.io/news/n97wtt7/prelude-therapeutics-receives-fda-clearance-of-investigational-new-drug-ind-application-fo 2026-09-10 never 0.6 https://aktiv8.io/news/n1pzycf2/abbvie-extends-migraine-leadership-with-positive-phase-3-atogepant-results-in-menstrual-mi 2026-09-10 never 0.6 https://aktiv8.io/news/n1kqzc50/alebund-secures-us-fda-ind-clearance-for-first-in-class-iga-nephropathy-therapy-ap308-biop 2026-09-10 never 0.6 https://aktiv8.io/news/nzp9rtp/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-to-showcase-zipalertinib- 2026-09-10 never 0.6 https://aktiv8.io/news/nr3f6zu/biohaven-epilepsy-drug-suffers-fda-hold-days-after-attracting-350m-deal 2026-09-10 never 0.6 https://aktiv8.io/news/nubrlrl/shoulder-innovations-receives-fda-510-k-clearance-for-n-22-humeral-head-and-initiates-full 2026-09-10 never 0.6 https://aktiv8.io/news/nmbs0zx/cullinan-therapeutics-to-host-virtual-analyst-and-investor-event-to-showcase-zipalertinib- 2026-09-10 never 0.6 https://aktiv8.io/news/n1j7e6fw/evommune-gives-up-hope-for-mrgprx2-antagonist-to-treat-itch-after-latest-phase-2-fail 2026-09-09 never 0.6 https://aktiv8.io/news/n215e0t/just-evotec-biologics-advances-u-s-department-of-war-antibodies-against-orthopoxvirus-into 2026-09-09 never 0.6 https://aktiv8.io/news/nh5o51e/full-life-technologies-announces-u-s-fda-ind-clearance-and-australian-regulatory-clearance 2026-09-09 never 0.6 https://aktiv8.io/news/n4sdtvc/full-life-technologies-announces-u-s-fda-ind-clearance-and-australian-regulatory-clearance 2026-09-09 never 0.6 https://aktiv8.io/news/npo61yf/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-with-poly 2026-09-09 never 0.6 https://aktiv8.io/news/n18ducmn/hanchorbio-reaches-clinical-milestone-for-hcb101-as-us-fda-allows-continued-treatment-for- 2026-09-09 never 0.6 https://aktiv8.io/news/nnw4ddo/chilean-cobalt-corp-completes-phase-2-at-neore-rare-earth-project-advances-proposed-acquis 2026-09-09 never 0.6 https://aktiv8.io/news/n3gsxis/hanchorbio-reaches-clinical-milestone-for-hcb101-as-us-fda-allows-continued-treatment-for- 2026-09-09 never 0.6 https://aktiv8.io/news/n9t364r/luma-vision-secures-fda-clearance-advancing-procedural-intelligence-as-the-foundation-of-t 2026-09-09 never 0.6 https://aktiv8.io/news/n34yr26/marengo-therapeutics-completes-enrollment-in-phase-1-2-start-001-monotherapy-cohorts-and-s 2026-09-09 never 0.6 https://aktiv8.io/news/nps35kn/luma-vision-secures-fda-clearance-advancing-procedural-intelligence-as-the-foundation-of-t 2026-09-09 never 0.6 https://aktiv8.io/news/n9inj3e/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-demonstrat 2026-09-09 never 0.6 https://aktiv8.io/news/ns96li7/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biotech-innova 2026-09-09 never 0.6 https://aktiv8.io/news/n1o6tyl0/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-o 2026-09-09 never 0.6 https://aktiv8.io/news/ndrjkdf/tyra-biosciences-reports-initial-phase-2-surf302-results-supporting-the-first-potential-or 2026-09-09 never 0.6 https://aktiv8.io/news/nq24i62/ideaya-biosciences-and-servier-announce-first-patient-dosed-in-optimum-11-global-phase-3-r 2026-09-09 never 0.6 https://aktiv8.io/news/nf7g3fx/biomarin-announces-positive-results-of-phase-3-voxzogo-study-in-hypochondroplasia-publishe 2026-09-09 never 0.6 https://aktiv8.io/news/n1ahvtp8/ideaya-biosciences-and-servier-announce-first-patient-dosed-in-optimum-11-global-phase-3-r 2026-09-09 never 0.6 https://aktiv8.io/news/nrixsq2/bioness-and-onestep-partner-to-transform-mobility-rehabilitation-with-objective-movement-d 2026-09-09 never 0.6 https://aktiv8.io/news/n1m5axu9/tyra-biosciences-reports-initial-phase-2-surf302-results-supporting-the-first-potential-or 2026-09-09 never 0.6 https://aktiv8.io/news/nidw29d/context-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-ct-202-cntx-stock-n 2026-09-09 never 0.6 https://aktiv8.io/news/npkkipj/mosliciguat-advances-to-phase-3-phrontier-trial-after-phocus-study-shows-20-pvr-reduction- 2026-09-09 never 0.6 https://aktiv8.io/news/n1erxtae/emboline-receives-u-s-fda-510-k-clearance-for-emboliner-embolic-protection-system 2026-09-09 never 0.6 https://aktiv8.io/news/nvendvr/beeline-flies-into-phase-3-as-oral-lupus-drug-soars-past-placebo 2026-09-09 never 0.6 https://aktiv8.io/news/nwnj7je/emboline-receives-u-s-fda-510-k-clearance-for-emboliner-embolic-protection-system 2026-09-09 never 0.6 https://aktiv8.io/news/ne0quln/ose-immunotherapeutics-welcomes-first-patient-dosed-by-veloxis-in-the-phase-2-rengevity-20 2026-09-09 never 0.6 https://aktiv8.io/news/n30gby0/stat-arpa-h-to-invest-62-million-to-develop-fda-authorized-ai-to-help-treat-heart-failure 2026-09-09 never 0.6 https://aktiv8.io/news/n18ohe27/harbour-biomed-partner-solstice-oncology-announces-225-million-series-a-financing-to-advan 2026-09-09 never 0.6 https://aktiv8.io/news/n1kuuoxu/first-participant-dosed-in-first-in-human-phase-1-study-of-gzc8072-a-novel-ultra-long-acti 2026-09-09 never 0.6 https://aktiv8.io/news/nmiytng/biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplas 2026-09-09 never 0.6 https://aktiv8.io/news/n1xp8odc/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-by-investing-com-i 2026-09-09 never 0.6 https://aktiv8.io/news/n188o6ra/just-evotec-biologics-advances-u-s-department-of-war-antibodies-against-orthopoxvirus-into 2026-09-09 never 0.6 https://aktiv8.io/news/n1faxjzv/mighty-therapeutics-initiates-ind-enabling-studies-of-mytx-255-a-mitochondrial-targeted-th 2026-09-09 never 0.6 https://aktiv8.io/news/n1s4a4ni/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-investing-com 2026-09-09 never 0.6 https://aktiv8.io/news/n1it1crb/1cbio-lee-s-pharm-ink-license-agreement-for-parp1-inhibitor-in-china-southeast-asia-contra 2026-09-09 never 0.6 https://aktiv8.io/news/n8e5d6p/proqr-announces-first-participant-dosed-in-phase-1-study-of-ax-0811-and-virtual-investor-a 2026-09-09 never 0.6 https://aktiv8.io/news/nb6wmor/impact-biotech-announces-completion-of-treatment-in-phase-3-enlighted-trial-of-padeliporfi 2026-09-09 never 0.6 https://aktiv8.io/news/n1lu8xmp/pyxis-oncology-announces-positive-updated-data-from-phase-1 2026-09-09 never 0.6 https://aktiv8.io/news/n169vl91/seaport-therapeutics-reports-positive-topline-results-from-phase-1-driving-simulation-tria 2026-09-09 never 0.6 https://aktiv8.io/news/n16a17gx/pharvaris-charts-approval-course-for-swelling-disorder-drug-on-phase-iii-win 2026-09-09 never 0.6 https://aktiv8.io/news/n1dp6spf/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics- 2026-09-09 never 0.6 https://aktiv8.io/news/n7w8fdj/new-52-week-topline-open-label-data-from-phase-3-comp005-trial-the-power-of-another-comp36 2026-09-09 never 0.6 https://aktiv8.io/news/naj9ldm/massive-bio-and-precisca-announce-strategic-partnership-to-expand-cancer-patient-access-to 2026-09-09 never 0.6 https://aktiv8.io/news/n1dynydg/sotio-doses-first-patient-in-phase-1-2-cadencia-01-clinical-trial-of-sot109-a-cdh17-target 2026-09-09 never 0.6 https://aktiv8.io/news/n7i8m3q/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-o 2026-09-09 never 0.6 https://aktiv8.io/news/n1ac39i3/mannkind-and-rose-pharma-inc-enter-licensing-and 2026-09-09 never 0.6 https://aktiv8.io/news/np61mdj/intelligent-bio-solutions-submits-fda-510-k-package-for-intelligent-fingerprinting-drug-sc 2026-09-09 never 0.6 https://aktiv8.io/news/n1l68mk8/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biotech-innova 2026-09-09 never 0.6 https://aktiv8.io/news/n1dmdfc1/tyra-biosciences-reports-initial-phase-2-surf302-results-supporting-the-first-potential-or 2026-09-09 never 0.6 https://aktiv8.io/news/npxvvf3/wall-street-weighs-impact-on-dyn-stock-post-novartis-phase-3-failure-rbc-says-these-key-di 2026-09-09 never 0.6 https://aktiv8.io/news/n1lmdjfr/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-demonstrat 2026-09-09 never 0.6 https://aktiv8.io/news/nd3k7k5/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-develop-an-inh 2026-09-09 never 0.6 https://aktiv8.io/news/n2ay5u1/transcenta-wuxi-biologics-sign-hicb-licensing-deal-contract-pharma 2026-09-09 never 0.6 https://aktiv8.io/news/nfj3y6j/biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplas 2026-09-09 never 0.6 https://aktiv8.io/news/n1bbyct1/puretech-founded-entity-seaport-therapeutics-reports-positive-topline-results-from-phase-1 2026-09-09 never 0.6 https://aktiv8.io/news/nuwk3iw/vertex-health-announces-strategic-growth-with-addition-of-jared-saul-md-as-partner 2026-09-09 never 0.6 https://aktiv8.io/news/n6gdh8d/ideaya-biosciences-and-servier-announce-first-patient-dosed-in-optimum-11-global-phase-3-r 2026-09-09 never 0.6 https://aktiv8.io/news/n1yzjdvx/revvity-to-acquire-human-cell-design-to-advance-human-relevant-cell-models-for-metabolic-d 2026-09-09 never 0.6 https://aktiv8.io/news/n16st8np/disc-medicine-presents-initial-results-from-restore-pv-phase-2-trial-in-patients-with-poly 2026-09-09 never 0.6 https://aktiv8.io/news/nmhe6yo/pyxis-oncology-announces-positive-updated-data-from-phase-1-monotherapy-study-of-micvotaba 2026-09-09 never 0.6 https://aktiv8.io/news/n1r3jqx6/stat-pharmalittle-we-re-reading-about-an-astrazeneca-copd-win-the-fda-filling-key-jobs-and 2026-09-09 never 0.6 https://aktiv8.io/news/nrjngok/x4-pharmaceuticals-xfor-outlines-path-to-possible-2029-fda-approval-stock-titan 2026-09-09 never 0.6 https://aktiv8.io/news/n10jid9w/milagro-expands-role-with-constitution-surgery-alliance-adding-clinical-data-extraction-to 2026-09-09 never 0.6 https://aktiv8.io/news/nlq5slz/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-children-with 2026-09-09 never 0.6 https://aktiv8.io/news/n1rcm0fb/emulate-enters-final-stage-of-fda-istand-program-for-human-liver-chip-with-submission-of-q 2026-09-09 never 0.6 https://aktiv8.io/news/n1scx18w/oral-infigratinib-shows-meaningful-benefits-beyond-growth-within-52-weeks-in-children-with 2026-09-09 never 0.6 https://aktiv8.io/news/ndb5w28/robinson-pharma-accelerates-southern-california-expansion-with-over-115-million-in-propert 2026-09-09 never 0.6 https://aktiv8.io/news/nc7s4bt/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics- 2026-09-09 never 0.6 https://aktiv8.io/news/njobtsx/taiwan-s-obigen-pharma-to-unblind-phase-3-botox-trial-early-in-november-year-end-cash-rais 2026-09-09 never 0.6 https://aktiv8.io/news/n1hm1aa7/mannkind-and-rose-pharma-inc-enter-licensing-and 2026-09-09 never 0.6 https://aktiv8.io/news/n1hmufnv/partnership-for-quality-measurement-endorses-nkf-measure-to-advance-earlier-detection-of-c 2026-09-09 never 0.6 https://aktiv8.io/news/nzronca/harbour-biomed-partner-solstice-oncology-announces-225-million-series-a-financing-to-advan 2026-09-09 never 0.6 https://aktiv8.io/news/nr6e8dt/sobi-receives-us-fda-fast-track-designation-for-pacritinib-in-vexas-syndrome 2026-09-09 never 0.6 https://aktiv8.io/news/n1pistyo/emboline-receives-u-s-fda-510-k-clearance-for-emboliner-embolic-protection-system 2026-09-09 never 0.6 https://aktiv8.io/news/n1ebo9tz/twostep-therapeutics-announces-oversubscribed-62-5-million-series-a-financing-and-fda-clea 2026-09-09 never 0.6 https://aktiv8.io/news/n10ntew1/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital- 2026-09-09 never 0.6 https://aktiv8.io/news/nu3bkxq/novartis-shares-slide-after-neuromuscular-candidate-acquired-with-avidity-fails-phase-iii- 2026-09-09 never 0.6 https://aktiv8.io/news/n1q35zic/solstice-rises-with-225m-series-a-to-advance-next-gen-ctla-4-immunotherapy-into-phase-2 2026-09-09 never 0.6 https://aktiv8.io/news/nvabt45/mannkind-pushes-into-inhaled-glp-1-weight-loss-through-rose-pharma-licensing-deal-finance- 2026-09-09 never 0.6 https://aktiv8.io/news/n190nvq8/opus-genetics-reports-positive-phase-1-2-data-for-opgx-best1-in-best1-related-retinal-dise 2026-09-09 never 0.6 https://aktiv8.io/news/n1oht6rj/humacyte-announces-fda-authorization-extending-symvess-shelf-life-to-36-months 2026-09-09 never 0.6 https://aktiv8.io/news/n18rva5a/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-demonstrat 2026-09-09 never 0.6 https://aktiv8.io/news/nljsnqc/bms-reports-positive-data-from-phase-ii-quintessential-study-for-r-r-mm 2026-09-09 never 0.6 https://aktiv8.io/news/n1lzf369/mannkind-and-rose-pharma-inc-enter-licensing-and-collaboration-agreement-to-develop-an-inh 2026-09-09 never 0.6 https://aktiv8.io/news/notvuuu/beeline-medicines-announces-positive-topline-results-from-global-phase-2-study-of-afimetor 2026-09-09 never 0.6 https://aktiv8.io/news/n1iwjtww/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-o 2026-09-09 never 0.6 https://aktiv8.io/news/nsousmz/fda-is-still-reviewing-rezolute-s-experimental-drug-no-timeline-is-set-stock-titan 2026-09-09 never 0.6 https://aktiv8.io/news/n10gvh61/rezolute-provides-update-on-fda-review-of-its-phase-3-sunrize-study-results-in-congenital- 2026-09-09 never 0.6 https://aktiv8.io/news/nzxpxn6/compass-pathways-new-52-week-topline-open-label-data-from-phase-3-comp005-trial-demonstrat 2026-09-09 never 0.6 https://aktiv8.io/news/n1nvua5c/compass-pathways-reports-52-week-phase-3-comp005-results-for-comp360 2026-09-09 never 0.6 https://aktiv8.io/news/n1lgjimf/pyxis-oncology-announces-positive-updated-data-from-phase-1-monotherapy-study-of-micvotaba 2026-09-09 never 0.6 https://aktiv8.io/news/n1svo7a7/ideaya-biosciences-doses-first-patient-in-phase-3-trial-grafa-com 2026-09-09 never 0.6 https://aktiv8.io/news/nw5rwac/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-by-investing-com-i 2026-09-09 never 0.6 https://aktiv8.io/news/n1q6gpre/radiopharm-theranostics-announces-positive-data-from-the-phase-1-imaging-trial-of-rad301-i 2026-09-09 never 0.6 https://aktiv8.io/news/n1xuhxpv/ucb-receives-u-s-fda-breakthrough-therapy-designation-for-cimzia-certolizumab-pegol-in-pre 2026-09-09 never 0.6 https://aktiv8.io/news/n1967o59/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-by-investing-com-i 2026-09-09 never 0.6 https://aktiv8.io/news/n1jcfwwv/cranius-therapeutics-receives-fda-510-k-clearance-for-the-cranius-plate-a-patient-specific 2026-09-09 never 0.6 https://aktiv8.io/news/n1ylwmzt/adagene-achieves-milestone-in-collaboration-with-exelixis-for-advancement-of-safebody-anti 2026-09-09 never 0.6 https://aktiv8.io/news/nldtyfd/pharvaris-latest-phase-3-win-builds-case-for-hae-drug-with-fda-verdict-pending 2026-09-08 never 0.6 https://aktiv8.io/news/n1vb27pm/new-labcentral-program-the-loop-offers-international-biotech-start-ups-and-partner-organiz 2026-09-08 never 0.6 https://aktiv8.io/news/n17yict6/abbott-receives-fda-approval-for-its-tactiflex-duo-ablation-catheter-to-treat-people-with- 2026-09-08 never 0.6 https://aktiv8.io/news/n7ca5r3/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-ra 2026-09-08 never 0.6 https://aktiv8.io/news/nk1yv4p/taiwan-s-horien-accelerates-global-footprint-achieves-three-thai-fda-class-4-approvals-and 2026-09-08 never 0.6 https://aktiv8.io/news/nem0b2c/dyne-therapeutics-to-present-additional-one-year-clinical-data-from-phase-1-2-achieve-tria 2026-09-08 never 0.6 https://aktiv8.io/news/n16lm05i/medicure-presents-mend-pnpo-phase-3-study-design-and-baseline-data-at-the-16th-european-ep 2026-09-08 never 0.6 https://aktiv8.io/news/n14m2kw5/upstream-bio-reports-phase-2-valiant-trial-results-showing-verekitug-reduced-severe-asthma 2026-09-08 never 0.6 https://aktiv8.io/news/n1cyotmu/pepromene-bio-annonce-la-publication-dans-the-lancet-des-resultats-d-un-essai-clinique-de- 2026-09-08 never 0.6 https://aktiv8.io/news/nktdmuu/alebund-pharmaceuticals-announces-fda-clearance-of-ind-application-for-ap308-for-the-treat 2026-09-08 never 0.6 https://aktiv8.io/news/n1quv7ft/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/nuvebtx/alebund-pharmaceuticals-announces-fda-clearance-of-ind-application-for-ap308-for-the-treat 2026-09-08 never 0.6 https://aktiv8.io/news/n1ndt7vo/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/ng6kyee/alebund-pharmaceuticals-announces-fda-clearance-of-ind-application-for-ap308-for-the-treat 2026-09-08 never 0.6 https://aktiv8.io/news/n141pond/kelun-biotech-s-partner-windward-bio-announces-positive-phase-2-results-of-skb378-win378-i 2026-09-08 never 0.6 https://aktiv8.io/news/nzutuem/a-breakthrough-blood-test-for-prostate-cancer-to-be-premiered-by-5q-spectra-at-davos-of-he 2026-09-08 never 0.6 https://aktiv8.io/news/nj14uvh/vor-completes-enrollment-of-global-phase-3-upstream-mg-trial-and-expands-telitacicept-glob 2026-09-08 never 0.6 https://aktiv8.io/news/nf1l5a7/beam-therapeutics-presents-updated-clinical-data-from-the-phase-1-2-trial-of-beam-302-in-a 2026-09-08 never 0.6 https://aktiv8.io/news/n7ksh51/fda-approves-astrazeneca-breast-cancer-drug-statnews-com 2026-09-08 never 0.6 https://aktiv8.io/news/n6elm7/vor-biopharma-vor-completes-enrollment-in-phase-3-trial-as-market-eyes-growth-potential-gu 2026-09-08 never 0.6 https://aktiv8.io/news/n1y89bkx/pharvaris-latest-phase-3-win-builds-case-for-hae-drug-with-fda-verdict-pending 2026-09-08 never 0.6 https://aktiv8.io/news/nby33xd/clearmind-medicine-receives-yale-irb-approval-enabling-patient-recruitment-for-parts-b-and 2026-09-08 never 0.6 https://aktiv8.io/news/n1h5eydf/amkor-technology-announces-phase-2-of-arizona-advanced-packaging-and-test-campus-expands-i 2026-09-08 never 0.6 https://aktiv8.io/news/n144qozp/adlai-nortye-announces-first-patient-dosed-in-australia-and-u-s-fda-ind-clearance-for-an40 2026-09-08 never 0.6 https://aktiv8.io/news/ntpnbwz/protocol-behavioral-health-partners-with-new-york-cancer-blood-specialists-to-bring-integr 2026-09-08 never 0.6 https://aktiv8.io/news/nfwowc3/stat-fda-warns-an-api-supplier-about-residue-on-walls-a-corroded-product-line-and-open-toe 2026-09-08 never 0.6 https://aktiv8.io/news/n2mj08v/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally 2026-09-08 never 0.6 https://aktiv8.io/news/n10h79vq/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-ra 2026-09-08 never 0.6 https://aktiv8.io/news/nqpfkzq/inhibrx-s-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-of-9-6-mo 2026-09-08 never 0.6 https://aktiv8.io/news/n3ea0rp/accro-bioscience-announces-ind-clearance-from-nmpa-for-phase-ii-iii-clinical-trial-of-ac-2 2026-09-08 never 0.6 https://aktiv8.io/news/n1p7da0l/kelun-biotech-s-partner-windward-bio-announces-positive-phase-2-results-of-skb378-win378-i 2026-09-08 never 0.6 https://aktiv8.io/news/nkbkf60/inhibrx-s-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-of-9-6-mo 2026-09-08 never 0.6 https://aktiv8.io/news/n1xoej9g/kiora-pharmaceuticals-appoints-keith-j-lane-as-executive-vice-president-of-global-clinical 2026-09-08 never 0.6 https://aktiv8.io/news/n1q1qigp/biovie-announces-update-to-parkinson-s-phase-3-development-program-bivi-stock-news 2026-09-08 never 0.6 https://aktiv8.io/news/nswxwag/inhibrx-s-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-of-9-6-mo 2026-09-08 never 0.6 https://aktiv8.io/news/n6kyuo9/pulmovant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pul 2026-09-08 never 0.6 https://aktiv8.io/news/n1n6fqb0/structure-therapeutics-reports-positive-clinical-data-across-oral-small-molecule-amylin-an 2026-09-08 never 0.6 https://aktiv8.io/news/nv8f2yk/biotech-filed-for-bankruptcy-11-weeks-before-its-big-fda-decision-thestreet-com 2026-09-08 never 0.6 https://aktiv8.io/news/n1xhmdfz/ge-healthcare-aims-to-advance-a-new-era-in-theranostics-with-starguide-gx-4d-spect-ct-now- 2026-09-08 never 0.6 https://aktiv8.io/news/n1ap1dy6/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/n1pkjp1f/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-prior 2026-09-08 never 0.6 https://aktiv8.io/news/njkohfn/biovie-advances-parkinson-s-phase-3-trial-plans-after-positive-phase-2-results-and-fda-eng 2026-09-08 never 0.6 https://aktiv8.io/news/nf80f6e/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-prior 2026-09-08 never 0.6 https://aktiv8.io/news/n1n2re41/bristol-myers-squibb-announces-positive-topline-results-from-registrational-phase-2-quinte 2026-09-08 never 0.6 https://aktiv8.io/news/n1cty5y2/palantir-and-nebius-partner-to-deliver-a-complete-sovereign-ai-stack-to-palantir-customers 2026-09-08 never 0.6 https://aktiv8.io/news/n16fzq17/bristol-myers-pivotal-car-t-multiple-myeloma-trial-hits-primary-endpoint 2026-09-08 never 0.6 https://aktiv8.io/news/nwwfdx5/artiva-biotherapeutics-announces-planned-2026-data-readouts-and-phase-3-trial-initiation-f 2026-09-08 never 0.6 https://aktiv8.io/news/n9ahb41/biovie-announces-next-stage-of-fda-engagement-for-phase-3-parkinson-s-disease-program-eval 2026-09-08 never 0.6 https://aktiv8.io/news/n1tmttly/intellia-announces-fda-acceptance-of-bla-for-lonvo-z-with-pdufa-date-march-10-2027-trading 2026-09-08 never 0.6 https://aktiv8.io/news/n1wwjnnk/pharvaris-announces-positive-topline-data-from-chapter-3-pivotal-study-of-deucrictibant-xr 2026-09-08 never 0.6 https://aktiv8.io/news/n34j9g5/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-initiation-of-phas 2026-09-08 never 0.6 https://aktiv8.io/news/n3i4j27/a-quarterly-dose-cut-asthma-flare-ups-56-versus-a-dummy-treatment-upstream-bio-plans-phase 2026-09-08 never 0.6 https://aktiv8.io/news/n1fb7321/stat-fda-approves-astrazeneca-breast-cancer-drug 2026-09-08 never 0.6 https://aktiv8.io/news/n8hs1p3/pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-r 2026-09-08 never 0.6 https://aktiv8.io/news/nf5a2s7/roivant-s-14m-bet-on-bayer-s-inhaled-hypertension-med-pays-off-with-phase-2-win 2026-09-08 never 0.6 https://aktiv8.io/news/nwig44r/sudarshan-pharma-industries-to-acquire-9-5-stake-in-us-based-medtherapy-biotech-outlookbus 2026-09-08 never 0.6 https://aktiv8.io/news/n1bzpxru/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally 2026-09-08 never 0.6 https://aktiv8.io/news/n52l9n6/probiogen-grants-transgene-additional-license-for-age1-cr-pix-cell-line 2026-09-08 never 0.6 https://aktiv8.io/news/nc0g2jx/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-3-test 2026-09-08 never 0.6 https://aktiv8.io/news/n121c4v5/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally 2026-09-08 never 0.6 https://aktiv8.io/news/n6d3wn/metashape-pharma-to-showcase-new-data-and-strategic-updates-at-medinvest-and-resi-life-sci 2026-09-08 never 0.6 https://aktiv8.io/news/n14ogl5v/roivant-announces-positive-results-from-phocus-study-of-mosliciguat-in-patients-with-pulmo 2026-09-08 never 0.6 https://aktiv8.io/news/n163nldv/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabeti 2026-09-08 never 0.6 https://aktiv8.io/news/nkzwexx/veru-advances-oral-sabizabulin-following-positive-preclinical-data-showing-potent-anticanc 2026-09-08 never 0.6 https://aktiv8.io/news/n1quas3p/labcorp-acquires-mlm-medical-labs-expanding-global-central-laboratory-and-biomarker-capabi 2026-09-08 never 0.6 https://aktiv8.io/news/n1etao4n/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-initiation-of-phas 2026-09-08 never 0.6 https://aktiv8.io/news/n1xfdso2/sernova-and-seraxis-enter-definitive-merger-agreement-to-create-a-differentiated-type-1-di 2026-09-08 never 0.6 https://aktiv8.io/news/n13jx6rm/surrozen-announces-submission-of-ind-application-for-szn-8141-for-the-treatment-of-diabeti 2026-09-08 never 0.6 https://aktiv8.io/news/n2su6ow/adlai-nortye-announces-first-patient-dosed-in-australia-and-u-s-fda-ind-clearance-for-an40 2026-09-08 never 0.6 https://aktiv8.io/news/n1nvwqnt/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatmen 2026-09-08 never 0.6 https://aktiv8.io/news/nenrl9s/newron-reports-subscription-for-eur-5-5-million-of-shares-by-investor-group-as-part-of-up- 2026-09-08 never 0.6 https://aktiv8.io/news/n1nurpbf/novartis-stock-slides-as-centerpiece-of-12b-avidity-buyout-flunks-crucial-phase-3-test 2026-09-08 never 0.6 https://aktiv8.io/news/n19zuyw6/helixgate-biotech-review-brings-helixgate-ai-biotech-collaboration-series-and-helixgate-in 2026-09-08 never 0.6 https://aktiv8.io/news/nta9nwz/newron-secures-eur-5-5m-financing-for-evenamide-phase-3-program-wboc-com 2026-09-08 never 0.6 https://aktiv8.io/news/ndln6qz/novartis-cholesterol-lowering-medicine-fails-phase-3-clouding-lp-a-horizons-biospace 2026-09-08 never 0.6 https://aktiv8.io/news/n1de1d1s/accro-bioscience-announces-ind-clearance-from-nmpa-for-phase-ii-iii-clinical-trial-of-ac-2 2026-09-08 never 0.6 https://aktiv8.io/news/n1d0zml2/stat-fda-names-acting-heads-of-drug-and-vaccine-centers-to-permanent-roles 2026-09-08 never 0.6 https://aktiv8.io/news/nrbul0r/pharvaris-announces-positive-phase-3-results-for-deucrictibant-xr-in-hereditary-angioedema 2026-09-08 never 0.6 https://aktiv8.io/news/n1lrx88z/dyne-therapeutics-to-present-additional-one-year-clinical-data-from-phase-1-2-achieve-tria 2026-09-08 never 0.6 https://aktiv8.io/news/nwlsung/biovie-announces-update-to-parkinson-s-phase-3-development-program 2026-09-08 never 0.6 https://aktiv8.io/news/nzps7jf/amgen-announces-landmark-results-from-the-phase-3-dellphi-305-study-demonstrating-statisti 2026-09-08 never 0.6 https://aktiv8.io/news/nq9lpqm/can-fite-reports-q2-2026-financial-results-and-ongoing-clinical-progress-highlighting-long 2026-09-08 never 0.6 https://aktiv8.io/news/n1nhqbqr/can-fite-reports-q2-2026-financial-results-and-ongoing-clinical-progress-highlighting-long 2026-09-08 never 0.6 https://aktiv8.io/news/ngg5sv8/can-fite-reports-q2-2026-financial-results-and-ongoing-clinical-progress-highlighting-long 2026-09-08 never 0.6 https://aktiv8.io/news/n1auw8iw/biovie-announces-update-to-parkinson-s-phase-3-development-program-stock-titan 2026-09-08 never 0.6 https://aktiv8.io/news/nobgslk/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-prior 2026-09-08 never 0.6 https://aktiv8.io/news/nmyid4t/ribox-therapeutics-receives-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designatio 2026-09-08 never 0.6 https://aktiv8.io/news/n11k9hp5/biovie-announces-update-to-parkinson-s-phase-3-development-program-markets-businessinsider 2026-09-08 never 0.6 https://aktiv8.io/news/n1xc33o3/orphalan-initiates-global-phase-3-traditional-study-of-investigational-once-daily-trientin 2026-09-08 never 0.6 https://aktiv8.io/news/nim6a1a/bristol-myers-squibb-announces-positive-topline-results-from-registrational-phase-2-quinte 2026-09-08 never 0.6 https://aktiv8.io/news/n1cj0tlw/genflow-biosciences-plc-announces-primary-endpoint-in-slab-clinical-trial-met-genff-stock- 2026-09-08 never 0.6 https://aktiv8.io/news/n8i7qs8/newron-reports-subscription-for-eur-5-5-million-of-shares-by-investor-group-as-part-of-up- 2026-09-08 never 0.6 https://aktiv8.io/news/n7cf36c/astrazeneca-tozorakimab-copd-phase-3-trial-results-2026 2026-09-08 never 0.6 https://aktiv8.io/news/n5rua8t/novo-nordisk-s-wegovy-helps-free-40-of-kids-from-obesity-in-phase-3-trial-fiercepharma-com 2026-09-08 never 0.6 https://aktiv8.io/news/nuwnmh1/new-labcentral-program-the-loop-offers-international-biotech-start-ups-and-partner-organiz 2026-09-08 never 0.6 https://aktiv8.io/news/n27c22x/applied-biologics-welcomes-new-cms-rapid-pathway-and-expanded-cms-fda-coordination-for-inn 2026-09-08 never 0.6 https://aktiv8.io/news/n2mpm38/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatmen 2026-09-08 never 0.6 https://aktiv8.io/news/n1hhdh13/oral-obesity-drug-shows-double-digit-weight-loss-as-structure-therapeutics-nasdaq-gpcr-adv 2026-09-08 never 0.6 https://aktiv8.io/news/nirkqgu/altesa-biosciences-presents-novel-clinical-data-demonstrating-vapendavir-significantly-red 2026-09-08 never 0.6 https://aktiv8.io/news/n1tcbxha/bioage-labs-announces-first-participant-dosed-in-quell-dme-a-phase-2-trial-of-bge-102-a-no 2026-09-08 never 0.6 https://aktiv8.io/news/n1eayudz/belite-bio-announces-submission-of-new-drug-application-to-the-ministry-of-health-labour-a 2026-09-08 never 0.6 https://aktiv8.io/news/n1an8pq4/moonwalk-to-use-70-million-to-develop-rnai-therapies-for-obesity-cardiometabolic-disease 2026-09-08 never 0.6 https://aktiv8.io/news/n1uiaove/sernova-and-seraxis-enter-definitive-merger-agreement-to-create-a-differentiated-type-1-di 2026-09-08 never 0.6 https://aktiv8.io/news/n3arwsw/labcorp-acquires-mlm-medical-labs-expanding-global-central-laboratory-and-biomarker-capabi 2026-09-08 never 0.6 https://aktiv8.io/news/n1nq6dq/semaglutide-improves-bmi-category-in-phase-3-pediatric-obesity-trial-patientcareonline-com 2026-09-08 never 0.6 https://aktiv8.io/news/n36e79w/novartis-pelacarsen-fails-to-meet-primary-endpoint-in-lp-a-horizon-trial 2026-09-07 never 0.6 https://aktiv8.io/news/nxcb5kz/acepodia-secures-fda-clearance-to-begin-phase-i-ace723-trial 2026-09-07 never 0.6 https://aktiv8.io/news/n8m1zl3/hagens-berman-alerts-capricor-therapeutics-inc-nasdaq-capr-investors-to-fda-review-extensi 2026-09-07 never 0.6 https://aktiv8.io/news/nppcw2i/brainchild-bio-masterminds-116m-series-a-for-car-t-s-pivotal-push-in-pediatric-brain-cance 2026-09-07 never 0.6 https://aktiv8.io/news/nacuq0t/novo-nordisk-step-young-phase-3-data-40-4-of-children-living-with-obesity-achieved-a-bmi-b 2026-09-07 never 0.6 https://aktiv8.io/news/nfkqram/novo-nordisk-step-young-phase-3-data-40-4-of-children 2026-09-07 never 0.6 https://aktiv8.io/news/n2ltgdj/sudarshan-pharma-industries-to-acquire-9-5-stake-in-us-based-medtherapy-biotech-thebluntti 2026-09-07 never 0.6 https://aktiv8.io/news/n1qpshjw/novartis-lp-a-drug-misses-phase-3-endpoint-european-biotechnology-magazine 2026-09-07 never 0.6 https://aktiv8.io/news/n1u8h28c/sudarshan-pharma-acquires-9-5-in-medtherapy-vohnetwork-com 2026-09-07 never 0.6 https://aktiv8.io/news/niciw0n/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-07 never 0.6 https://aktiv8.io/news/nay31s0/clover-announces-positive-phase-2-clinical-data-for-rsv-hmpv-piv3-respiratory-combination- 2026-09-06 never 0.6 https://aktiv8.io/news/n1tzwfic/roivant-s-14m-bet-on-bayer-s-inhaled-hypertension-med-pays-off-with-phase-2-win 2026-09-06 never 0.6 https://aktiv8.io/news/n1jtkpe4/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat-in-patient 2026-09-06 never 0.6 https://aktiv8.io/news/niyrq7a/inhibrx-to-present-inbrx-106-phase-2-data-in-head-and-neck-cancer-study-the-clinical-trial 2026-09-05 never 0.6 https://aktiv8.io/news/n1m19x88/crispr-therapeutics-gains-fda-approval-for-casg-pluang-com 2026-09-05 never 0.6 https://aktiv8.io/news/n7fjjw6/will-positive-phase-3-deucrictibant-data-in-hae-redefine-pharvaris-phvs-orphan-drug-narrat 2026-09-05 never 0.6 https://aktiv8.io/news/nhtw683/pelacarsen-fails-to-meet-primary-endpoint-in-phase-3-lp-a-trial-the-clinical-trial-vanguar 2026-09-05 never 0.6 https://aktiv8.io/news/nz6qdtq/lupin-receives-u-s-fda-approval-for-modafinil-tablets-usp 2026-09-04 never 0.6 https://aktiv8.io/news/nvy6idv/constar-factory-announces-fda-510-k-cleared-contact-lens-oem-solutions-for-us-importers-an 2026-09-04 never 0.6 https://aktiv8.io/news/nxmq2r5/acepodia-announces-fda-clearance-of-ind-application-for-ace723-a-novel-dual-payload-antibo 2026-09-04 never 0.6 https://aktiv8.io/news/n1mckfa9/lupin-receives-u-s-fda-approval-for-modafinil-tablets-usp 2026-09-04 never 0.6 https://aktiv8.io/news/n1fohdns/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the- 2026-09-04 never 0.6 https://aktiv8.io/news/n106hagj/ionis-rare-neurology-drug-approved-pfizer-inks-an-adc-deal 2026-09-04 never 0.6 https://aktiv8.io/news/nq383lw/this-week-in-charts-china-deals-stock-flatlines-and-lilly-s-m-a-spree 2026-09-04 never 0.6 https://aktiv8.io/news/nf0eq0x/the-friday-brief-for-september-4-2026-licensing-deals-dominate-the-week-contract-pharma 2026-09-04 never 0.6 https://aktiv8.io/news/n1744viz/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-for-inbrx-106-pha 2026-09-04 never 0.6 https://aktiv8.io/news/n19yrqmf/stat-fda-takes-another-look-at-botanical-drugs 2026-09-04 never 0.6 https://aktiv8.io/news/n1yjktp/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-04 never 0.6 https://aktiv8.io/news/n10fvjuz/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-04 never 0.6 https://aktiv8.io/news/nyc8rok/stat-novartis-experimental-cardiovascular-drug-fails-a-pivotal-study 2026-09-04 never 0.6 https://aktiv8.io/news/n3iut9d/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-04 never 0.6 https://aktiv8.io/news/nuxqkpf/abbvie-abbv-reports-positive-phase-3-results-for-etentamig-in-multiple-myeloma 2026-09-04 never 0.6 https://aktiv8.io/news/n6ee32f/c4x-discovery-to-receive-milestone-payment-for-nrf2-exclusive-worldwide-license-agreement 2026-09-04 never 0.6 https://aktiv8.io/news/n1fp0jay/sino-biopharmaceutical-s-gpc3-adc-drug-wins-fda-clinical-trial-approval-shares-surge-nearl 2026-09-04 never 0.6 https://aktiv8.io/news/n1isywyo/cluepoints-launches-ai-tools-for-clinical-data-review-with-top-10-pharma-partner-the-clini 2026-09-04 never 0.6 https://aktiv8.io/news/n7ipwe5/medicus-pharma-licenses-pfizer-s-discontinued-cd228-targeted-adc-in-deal-worth-over-1-bill 2026-09-04 never 0.6 https://aktiv8.io/news/n1nj8132/medicus-pharma-licenses-shelved-pfizer-melanoma-adc-in-deal-worth-up-to-1b-dealroom 2026-09-04 never 0.6 https://aktiv8.io/news/nhqck8c/novartis-announces-lp-a-horizon-phase-iii-topline-results-for-pelacarsen-in-patients-with- 2026-09-04 never 0.6 https://aktiv8.io/news/nwanstx/this-biotech-wins-a-big-fda-approval-why-wall-street-is-shrugging-barron-s 2026-09-04 never 0.6 https://aktiv8.io/news/n1dqvmjn/acepodia-announces-fda-clearance-of-ind-application-for-ace723-a-novel-dual-payload-antibo 2026-09-04 never 0.6 https://aktiv8.io/news/n1qstkxo/gilead-s-growing-hiv-franchise-cell-therapy-licensing-deals-plummet-pharma-voice 2026-09-04 never 0.6 https://aktiv8.io/news/n18q8ftn/royalty-pharma-announces-update-on-novartis-phase-3-topline-results-for-pelacarsen-rprx-st 2026-09-04 never 0.6 https://aktiv8.io/news/nmp8c7w/ionis-partner-novartis-announces-lp-a-horizon-phase-3-topline-results-for-pelacarsen-in-pa 2026-09-04 never 0.6 https://aktiv8.io/news/n1akans4/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-for-inbrx-106-pha 2026-09-04 never 0.6 https://aktiv8.io/news/ntw4pus/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-04 never 0.6 https://aktiv8.io/news/nf645da/tyra-biosciences-to-host-conference-call-on-initial-results-of-oral-dabogratinib-from-the- 2026-09-04 never 0.6 https://aktiv8.io/news/ny811x3/ivonescimab-beats-pembrolizumab-on-overall-survival-in-phase-3-nsclc-trial-clinicaltrialva 2026-09-04 never 0.6 https://aktiv8.io/news/nw5jszf/sensorion-secures-approval-for-hearconnex-phase-i-ii-study-in-france 2026-09-04 never 0.6 https://aktiv8.io/news/njejh9g/guardant-health-announces-landmark-fda-approval-of-guardant360 2026-09-04 never 0.6 https://aktiv8.io/news/ncg8v3l/royalty-pharma-announces-update-on-novartis-phase-3-topline-results-for-pelacarsen-the-man 2026-09-04 never 0.6 https://aktiv8.io/news/n1wq7lsy/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig 2026-09-03 never 0.6 https://aktiv8.io/news/n1rzkq61/thryv-therapeutics-licenses-a-new-class-of-sgk1-inhibitors-from-spain-s-csic-and-universid 2026-09-03 never 0.6 https://aktiv8.io/news/nkeydhr/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductions 2026-09-03 never 0.6 https://aktiv8.io/news/n17irvq3/medicus-pharma-inks-global-licensing-deal-with-pfizer-worth-over-1-billion-benzinga 2026-09-03 never 0.6 https://aktiv8.io/news/n18p6z55/hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer-th 2026-09-03 never 0.6 https://aktiv8.io/news/naaiym1/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-03 never 0.6 https://aktiv8.io/news/n1074j1d/ultragenyx-drops-on-phase-3-trial-failure-for-angelman-syndrome-drug-rare-nasdaq 2026-09-03 never 0.6 https://aktiv8.io/news/n1w73rz9/matricelf-receives-fda-feedback-supporting-key-elements-of-proposed-first-in-human-clinica 2026-09-03 never 0.6 https://aktiv8.io/news/nmtijid/legacy-healthcare-welcomes-u-s-congressional-legislation-proposing-12-year-market-exclusiv 2026-09-03 never 0.6 https://aktiv8.io/news/n1ot5961/gan-lee-and-menarini-group-partner-to-advance-bofanglutide-in-europe 2026-09-03 never 0.6 https://aktiv8.io/news/nbqe4dj/treeline-and-roche-collaborate-on-tln-121-combo-trial-for-bcl 2026-09-03 never 0.6 https://aktiv8.io/news/n19axxqt/biogen-biib-fda-approvals-pdufa-dates-drug-alerts-2026-biib-marketbeat 2026-09-03 never 0.6 https://aktiv8.io/news/n1nluiuf/leqembi-lecanemab-subcutaneous-formulation-as-an-initiation-treatment-for-early-alzheimer- 2026-09-03 never 0.6 https://aktiv8.io/news/nyv37qg/revmed-s-newly-approved-rasonque-could-hold-up-in-non-small-cell-lung-cancer-biospace 2026-09-03 never 0.6 https://aktiv8.io/news/n1o1sta8/c4-therapeutics-to-present-new-biomarker-data-on-the-immunomodulatory-effects-of-cemsidomi 2026-09-03 never 0.6 https://aktiv8.io/news/nqx472o/climb-bio-announces-clym116-phase-1-data-demonstrating-prolonged-half-life-and-best-in-cla 2026-09-03 never 0.6 https://aktiv8.io/news/n128hk3m/cipla-qilu-enter-licensing-and-supply-deal-for-keytruda-biosimilar-in-us-contract-pharma 2026-09-03 never 0.6 https://aktiv8.io/news/nrypbee/pfizer-licenses-discontinued-cancer-drug-to-medicus-pharma-in-deal-valued-over-1-billion-f 2026-09-03 never 0.6 https://aktiv8.io/news/n19dkz7c/ultragenyx-fails-phase-3-angelman-test-plots-significant-expense-reductions 2026-09-03 never 0.6 https://aktiv8.io/news/n1br3s9t/kali-therapeutics-receives-u-s-fda-clearance-for-kt501-investigational-new-drug-applicatio 2026-09-03 never 0.6 https://aktiv8.io/news/n1o40tni/ivonescimab-meets-overall-survival-endpoint-against-pembrolizumab-in-phase-iii-trial-the-c 2026-09-03 never 0.6 https://aktiv8.io/news/nnbxdwz/eledon-pharmaceuticals-announces-islet-cell-transplantation-ind-submission-first-patients- 2026-09-03 never 0.6 https://aktiv8.io/news/ni5n6d3/ultragenyx-s-apazunersen-fails-phase-3-primary-endpoint-in-angelman-syndrome-the-clinical- 2026-09-03 never 0.6 https://aktiv8.io/news/n1j3qnvr/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig 2026-09-03 never 0.6 https://aktiv8.io/news/n9nr2s4/perfect-game-launches-new-global-country-partner-program-to-expand-international-baseball- 2026-09-03 never 0.6 https://aktiv8.io/news/nq98zbh/cellipont-bioservices-texas-facility-has-supported-six-client-projects-expected-to-reach-i 2026-09-03 never 0.6 https://aktiv8.io/news/nla8fiz/ultragenyx-s-apazunersen-fails-phase-3-angelman-syndrome-trial-biopharm-international 2026-09-03 never 0.6 https://aktiv8.io/news/n1txr4lr/abbvie-announces-positive-topline-results-from-the-phase-3-cervino-trial-showing-etentamig 2026-09-03 never 0.6 https://aktiv8.io/news/ng1aexd/stat-fda-pilot-offers-generative-ai-medical-devices-a-path-to-patients-before-they-are-aut 2026-09-03 never 0.6 https://aktiv8.io/news/n1hkziau/hutchmed-strikes-licensing-agreement-with-gsk-the-pharma-letter 2026-09-03 never 0.6 https://aktiv8.io/news/nj38hnr/hisense-extends-long-term-uefa-partnership-as-official-partner-of-uefa-euro-2028 2026-09-03 never 0.6 https://aktiv8.io/news/n2etaay/c4-therapeutics-to-present-new-biomarker-data-on-the-immunomodulatory-effects-of-cemsidomi 2026-09-03 never 0.6 https://aktiv8.io/news/n18xa2et/eledon-pharmaceuticals-announces-islet-cell-transplantation-ind-submission-first-patients- 2026-09-03 never 0.6